Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$15.08 USD
+0.20 (1.34%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $15.07 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth A Momentum A VGM
Price, Consensus and EPS Surprise
TAK 15.08 +0.20(1.34%)
Will TAK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TAK
ADMA Biologics (ADMA) Hits 52-Week High: More Room to Grow?
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
OVID Slumps 76% on Epilepsy Drug Failing Two Pivotal Studies
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Other News for TAK
Denali Therapeutics Continues To Have Plenty Of Moving Parts
Takeda Receives European Commission Approval for ADZYNMA?? (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda receives European Commission approval for ADZYNMA
Protagonist Therapeutics price target lowered to $43 from $45 at JMP Securities
Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder